Stockreport

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF SAN DIEGO, November 20, 2025 BUSINESS WIRE )--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneeri [Read more]